A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

Research Insight

Status and phase: Completed; Phase 4

Conditions: Cataract

Treatments: Drug: Prednisolone Acetate; Drug: Dexycu intracameral dexamethasone

Study type: Interventional

Funder types: Industry

Identifiers

NCT04273282

1909 D3 EyePoint

Details and patient eligibility

About

This is a post-approval, open-label, randomized, self-controlled prospective clinical study to evaluate the safety and ocular efficacy of Dexycu in controlling postoperative ocular pain and inflammation associated with cataract surgery.

Full description

On initial consultation, each study subject will be randomized by a table in the possession of investigators to receive one of two treatment groups, either experimental or control in the first eye. The second eye will undergo cataract surgery approximately 2 weeks later and will be treated with the other treatment group:

Dexycu Group: A total of 30 study subjects will have Dexycu intracameral dexamethasone placed in their scheduled surgical eye at the time of surgery and will receive 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure. They will take Prolensa each day after surgery for 4 weeks.

Control Group: A total of 30 study subjects will receive topical moxifloxacin 0.5% four times per day 1 day prior to surgery and for ten days postoperatively, Prolensa every day 1 day prior to surgery and for 4 weeks postoperatively, and prednisolone acetate 1.0% four times per day starting at the conclusion of cataract surgery for 2 weeks and twice per day for 2 weeks in their scheduled surgical eye.

Enrollment: 31 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• A male or female in good general health, greater than 18 years of age at time of screening.
• Must be able to comprehend and willing to give informed consent.
• Woman of child-bearing potential must not be pregnant or lactating.
• Subject has availability, willingness, and sufficient cognitive awareness to comply with exam procedures and able to return for all scheduled study visits.
• Subject with cataract for which routine phacoemulsification extraction and implantation of an intraocular lens has been planned.
• Subject with an OCT of the macula in both eyes that demonstrates no significant pathology.

Exclusion criteria

• Subject with any signs of intraocular inflammation in either eye at screening.
• Subject with a known sensitivity to any of the study medications.
• Subject with only one eye with potentially good vision.
• Subject that has undergone prior intraocular surgery in the scheduled surgical eye within the last 6 months or laser surgery within three months prior to screening.
• Subject with pupil abnormalities.
• Subject with corneal abnormalities.
• Subject with a history of chronic/recurrent inflammatory eye disease in either eye.
• Subject with uncontrolled glaucoma.
• Subject expected to undergo surgical intervention and/or ocular laser treatment prior to or during the study period.
• Subject who requires use of systemic or ocular medications that may affect vision, ocular inflammation, or pain.
• Subject with an acute or chronic disease or illness that would increase risk or confound study results, e.g. autoimmune disease, etc.
• Subject with an uncontrolled systemic disease.
• Subject with poorly-controlled diabetes.
• Subject currently participating or has participated in another clinical trial within 30 days prior to enrollment.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

31 participants in 2 patient groups

Dexycu Group

Active Comparator group

Description:

A total of 30 study subjects (30 eyes) will have Dexycu intracameral dexamethasone placed in their scheduled surgical eye at the time of surgery and will receive 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure. They will take Prolensa qd after surgery for 4 weeks.

Treatment:

Drug: Dexycu intracameral dexamethasone

Control Group

Active Comparator group

Description:

A total of 30 study subjects (30 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, Prolensa qd 1 day prior to surgery and for 4 weeks postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.

Treatment:

Drug: Prednisolone Acetate